SHPH

Shuttle Pharma is a pre-revenue clinical-stage shell burning through cash it does not have. FY2025 net loss was $11.7M (widening 28% YoY) against zero revenue, and the company ended the year with just $334K of cash (down 82.6% YoY) versus a $7.5M working-capital deficit. Management's own filing states the financials are prepared on a going-concern basis and that 'substantial doubt' exists about survival within one year — the single most important fact here, and it dominates everything else. Operating cash flow was -$9.48M; at that burn the $334K cash balance is effectively nothing, so continued existence depends entirely on serial dilutive equity raises.

The story is worse than a normal cash-strapped biotech because the thesis itself just changed. On November 20, 2025 the company committed to winding down the clinical trials of Ropidoxuridine — its lead asset — and one day earlier pivoted into an acquired AI drug-discovery platform, Molecule.ai. By management's own admission it 'currently do[es] not have any customers' for that platform and expects to derive 'a significant portion' of future revenue from license deals that do not yet exist. So investors are being asked to fund an abandoned clinical program replaced by a speculative software business with no commercial traction and integration risk explicitly flagged in the filing.